Galenica AG/ CH0360674466 /
11/23/2022 3:30:04 PM | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
75.2500USD | - | 800 Turnover: 60,200 |
-Bid Size: - | -Ask Size: - | 4.43 bill.USD | - | - |
GlobeNewswire
7/31
Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary
GlobeNewswire
7/25
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOL...
GlobeNewswire
9/18/2023
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
GlobeNewswire
11/17/2021
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
GlobeNewswire
8/19/2021
Biofrontera reports financial results for the six months ended June 30, 2021
GlobeNewswire
12/7/2020
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz®...
GlobeNewswire
7/11/2019
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer...
GlobeNewswire
6/18/2019
Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance O...
GlobeNewswire
5/23/2018
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensin...
GlobeNewswire
5/23/2018
VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE...
GlobeNewswire
5/8/2018
Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa®...
GlobeNewswire
4/16/2018
Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders
GlobeNewswire
4/11/2018
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at t...
GlobeNewswire
3/27/2018
VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN